Skip to main content

Table 1 Baseline characteristics, drug treatment and neurohormonal data stratified by UCP2 genotype group.

From: The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction

 

UCP2 Genotype

n

AA

n

GA

n

GG

p

Gender (M/F)

140

102/38(72.9%M)

410

309/101(75.4%M)

351

292/59 (83.2%M)

0.009

Age (years)*

140

61.5 ± 0.94

410

62.0 ± 0.49

350

62.7 ± 057

0.404

BMI* (kgm-2)

92

27.2 ± 0.51

285

26.9 ± 0.25

239

26.4 ± 0.25

0.174

LVEF

113

47.2 ± 1.00

348

48.0 ± 0.64

288

47.9 ± 0.72

0.822

Predischarge Mean arterial pressure (mmHg)

133

82.9 ± 0.87

397

83.2 ± 0.55

341

84.6 ± 0.61

0.145

Predischarge Systolic Blood pressure (mmHg)

133

117 ± 1.28

397

116 ± 0.81

341

118 ± 0.90

0.163

Predischarge Diastolic Blood pressure (mmHg)(mmHg)

133

65.9 ± 0.82

397

66.8 ± 0.54

341

67.8 ± 0.57

0.176

History

       

   Previous myocardial infarction*

127

24(18.9%)

389

72 (18.5%)

334

58 (17.4%)

0.896

   hypertension *

129

47(36.4%)

400

157 (39.3%)

342

131 (38.3%)

0.847

   Type 2 Diabetes*

139

22(15.8%)

409

48(11.7%)

349

38 (10.9%)

0.308

Predischarge Atrial Fibrillation*

Fibrillation*

112

12(10.7%)

346

35 (10.1%)

297

47 (15.8%)

0.076

   Predischarge Ventricular Fibrillation* Fibrillation*

113

11(9.7%)

355

40 11.3%)

300

21 (7.0%)

0.173

Laboratory Data

       

   Total Cholesterol* (mmol/l)

130

5.94 ± 0.10

376

5.95 ± 0.065

330

5.81 ± 0.068

0.325

   HDL Cholesterol* (mmol/l)

129

1.16 ± 0.026

371

1.16 ± 0.017

325

1.15 ± 0.018

0.913

   LDL Cholesterol* (mmol/l)

97

3.96 ± 0.10

299

3.98 ± 0.058

268

3.83 ± 0.069

0.225

   Triglycerides* (mmol/l)

130

2.02 ± 0.11

376

2.08 ± 0.096

330

2.01 ± 0.069

0.791

   Plasma Creatinine† (μmol/l)

136

83 (79–87)

405

85 (82–87)

347

85 (83–87)

0.600

   Creatinine Clearance* (ml/s)

99

1.28 ± 0.047

308

1.28 ± 0.023

267

1.32 ± 0.028

0.546

   Peak Creatine kinase† (units/l)

105

1440(1250–1660)

327

1610(1480–1740)

269

1640(1510–1680)

0.304

   Plasma Glucose (mmol/l)

137

8.55 ± 0.27

404

8.64 ± 0.15

344

8.55 ± 0.16

0.912

   Glycated Hemoglobin %

105

6.07 ± 0.11

324

6.06 ± 0.06

274

6.03 ± 0.06

0.905

Discharge Medications

       

   ACE inhibitor *

122

36(29.5%)

374

121 (32.4%)

318

109 (34.3%)

0.624

   β-blocker *

122

78(63.9%)

374

232 (62.0%)

318

176 (55.3%)

0.119

Neurohormonal Data

       

   ANP (pmol/l)‡

138

26.8(24.4–29.4)

403

28.5(27.0–30.0)

346

28.8(27.1–30.6)

0.406

   BNP (pmol/l)‡

138

18.2(16.4–20.2)

404

19.8(18.7–21.0)

346

19.9(18.8–21.1)

0.290

   NTproBNP (pmol/l)‡

137

98.6(87.0–112)

399

112(104–121)

344

111(103–121)

0.200

   Endothelin-1 (pmol/l)‡

137

1.64(1.52–1.77)

398

1.80(1.73–1.88)

340

1.76(1.167–1.81)

0.110

  1. *Means (SEM) or occurrence (percentage); †Median (range); ‡Geometric mean (95% confidence interval).
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840